EGRX — Eagle Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $12.99m
- $67.83m
- $316.61m
Eagle Pharma rises on FDA's expanded approval for lung cancer drug
Brief: Eagle Pharmaceuticals Gets FDA Approval For PEMFEXY Additional Indication
Brief: Eagle Pharmaceuticals Reaches Bendeka Settlement Agreement With Accord Healthcare
Brief: Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug For The Treatment Of Pneumonia
U.S. STOCKS ON THE MOVE-Boeing, U.S. energy, Delek US
Eagle Pharmaceuticals jumps after Q3 results beat
Eagle Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Eagle Pharmaceuticals Reports Third Quarter 2022 Results
Eagle Pharmaceuticals Inc expected to post earnings of 91cents a share - Earnings Preview
Brief: Eagle Pharmaceuticals Inc- Co Entered Into The Third Amended And Restated Credit Agreement
Brief: Eagle Pharmaceuticals Submits Investigational New Drug Application To U.S. FDA For Cal02, A Drug Meant For The Treatment Of Severe Community-Acquired Bacterial Pneumonia
Brief: Eagle Pharmaceuticals Files For Mixed Shelf Of Up To $200 Million
Eagle Pharma up on unit's $50.3 mln contract
Brief: Eagle Pharma And Enalare Therapeutics Announce Additional Award Worth Up To $50 Mln From BARDA To Advance Intramuscular Formulation Of ENA-001
Eagle Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkeley Lights, Minerva Surgical
Brief: Eagle Pharmaceuticals Takes Equity Stake In, With Option To Acquire, Enalare Therapeutics
Brief: Eagle Pharmaceuticals reports Q2 results
Brief: Eagle Pharmaceuticals Appoints Debra M. Hussain As SVP, Head Of Commercial